Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
PD-1 / PD-L1 antibodies block the programmed cell death protein 1 (PD-1) checkpoint on T cells or its ligand PD-L1. Binding of PD-L1 on tumor or antigen-presenting cells to PD-1 suppresses T-cell activation, so blocking either partner restores effector function in co-culture and tumor models. Anti-PD-1 antibodies in this group include pembrolizumab, nivolumab, cemiplimab, dostarlimab, tislelizumab and toripalimab. Atezolizumab, durvalumab and avelumab bind PD-L1 instead, and avelumab retains antibody-dependent cell-mediated cytotoxicity (ADCC). The antibodies serve as reference reagents in checkpoint blockade assays, receptor occupancy studies and combination experiments.
Synonyms: ATOR-1017
Evunzekibart (ATOR-1017) is a 4-1BB agonist that functions conditionally through Fc-γ receptor engagement, classified as an IgG4-type antibody. This biologic is designed to activate immune responses against cancer cells either as a standalone treatment or in synergy with anti-PD1 therapies, enhancing its potential for anticancer efficacy.
Cemiplimab, a monoclonal IgG4 antibody, exhibits high affinity for the programmed death receptor-1 (PD-1). It effectively blocks the PD-1/PD-L1 interaction, which is critical in mediating T-cell suppression. This antibody is predominantly utilized in the study of squamous cell carcinoma of the skin, providing a valuable tool for investigating immune checkpoint blockade therapies in cancer research.
Synonyms: JNJ 63723283; JNJ 3283
Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ monoclonal antibody that selectively targets the programmed death-1 (PD-1) receptor. This antibody exhibits a high affinity for PD-1 with a dissociation constant (Kd) of 1.72 nM, as determined in HEK293 cells. Cetrelimab effectively inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with half-maximal inhibitory concentrations (IC50) of 111.7 ng/mL and 138.6 ng/mL, respectively. By blocking this pathway, Cetrelimab activates peripheral T cells, leading to enhanced production of key cytokines such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α). This immunomodulatory effect contributes to its ability to suppress tumor growth in vivo, making it a valuable tool for cancer immunotherapy research.
Synonyms: MGD019
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART) designed to simultaneously inhibit the activity of PD-1 and CTLA-4 immune checkpoints. By blocking these pathways, Lorigerlimab enhances T-cell mediated immune responses, which are critical in the control and elimination of tumors. This antibody is particularly relevant for studies focused on metastatic castration-resistant prostate cancer (mCRPC), providing a valuable tool for research in immune checkpoint blockade therapies and their role in cancer immunology.
Synonyms: LVGN-3616
Pradusinstobart is a human IgG4 κ monoclonal antibody targeting PDCD1 (Programmed Cell Death Protein 1). For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.
Retifanlimab is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, designed to modulate immune responses in tumor microenvironments. This antibody is particularly utilized in the study of gastroesophageal adenocarcinoma (GEA), providing a valuable tool for researchers investigating the therapeutic potential of PD-1 inhibition in this cancer type.
Synonyms: LY3434172
Reozalimab is a bispecific antibody engineered to target both PD-1 and PD-L1. This unique formulation enhances the immune response against tumor cells by facilitating antibody-dependent cell-mediated cytotoxicity (ADCC). It is primarily utilized in oncological research to investigate immune checkpoint blockade therapies.
Synonyms: SHR-1316
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal antibody targeting PD-L1 within the PD-1/PD-L1 pathway. Demonstrating significant antitumor activity, this antibody is particularly effective in treating solid tumors, such as extensive-stage small-cell lung cancer (SCLC). Adebrelimab's mechanism of action involves modulating the immune response by inhibiting the PD-1/PD-L1 interaction, thereby enhancing the body's antitumor immune activity. This product is pivotal for research focused on immune checkpoint pathways and cancer immunotherapy.
Synonyms: TSR-042
Dostarlimab (TSR-042) is a humanized monoclonal antibody targeting PD-1 (Programmed Death-1). This antibody exhibits high affinity binding to PD-1, effectively blocking its interaction with the ligands PD-L1 and PD-L2. The inhibition constants (IC50) are determined to be 1.8 nM for PD-L1 and 1.5 nM for PD-L2, respectively. Dostarlimab serves as a potent inhibitor in the modulation of immune responses, making it a valuable tool in immunotherapy research.
The Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a chimeric mouse monoclonal antibody of the IgG2b, κ subclass, specifically designed to target human PD-L1, also known as B7-H1. This antibody has been developed for high specificity and affinity to PD-L1, an important immune checkpoint protein that plays a critical role in inhibiting the immune response, thereby enabling cancer cells to evade immune detection. For accurate experimental control, it is recommended to use the Mouse IgG2b kappa Isotype Control, which serves as a non-reactive baseline to assess the specific binding of the Anti-PD-L1/B7-H1 Antibody in various assays. This product is ideal for research applications focusing on cancer immunology and immune checkpoint regulation.
Synonyms: KN-046
Erfonrilimab (KN-046) is a bifunctional monoclonal antibody designed to simultaneously inhibit both PD-L1 and CTLA-4, two critical immune checkpoint proteins. This dual inhibition mechanism enhances the immune system's ability to recognize and destroy cancer cells, making it a promising therapeutic agent in oncology research. Erfonrilimab is specifically engineered for use in investigating the efficacy of combined checkpoint blockade in various cancer models.
Synonyms: ABBV 181; PR 1648817
Budigalimab (ABBV 181; PR 1648817) is a humanized recombinant IgG1 monoclonal antibody specifically designed to target the programmed cell death 1 (PD-1) receptor. This antibody features a modified Fc region with a mutation that diminishes Fc receptor interactions and effector function inhibition. By effectively blocking the interaction between PD-1 and its ligand PD-L1, Budigalimab exhibits potent anti-tumor activity. It is primarily utilized in research focused on various solid tumors, providing a valuable tool for oncology studies.
Synonyms: CX-072
Pacmilimab (CX-072) is a potent inhibitor of programmed death-ligand 1 (PD-L1), exhibiting significant antitumor activity. This monoclonal antibody selectively binds to PD-L1, disrupting its interaction with PD-1 receptors on T cells, thereby enhancing the immune system's ability to attack tumor cells. Pacmilimab is primarily utilized in research focused on the modulation of immune checkpoints in oncology.
Amostomig is a humanized IgG1λ2 monoclonal antibody designed to specifically target CD274 and CD47. For experimental control purposes, the recommended isotype control is Human IgG1 lambda2.
Simridarlimab is a humanized immunoglobulin (Ig) antibody that specifically targets the CD274 and CD47 antigens. This dual targeting approach enhances the antibody's ability to modulate the immune response against cancer cells, making it a valuable tool in oncological research and therapeutic development.
Synonyms: LDP
Lesabelimab (LDP) is a monoclonal antibody of the immunoglobulin G1-kappa class, specifically targeting CD274, also known as PD-L1. CD274 functions as an immune checkpoint ligand that inhibits antitumor immune responses by engaging the PDCD1 (PD-1) receptor. This interaction is crucial for modulating immune system activity, particularly in the suppression of T-cell mediated immunity in various cancers. Lesabelimab is designed to disrupt this interaction, thereby enhancing the body's antitumor immune response. This antibody is pivotal for research focused on cancer immunotherapy and the study of immune checkpoint pathways.
Synonyms: BMS-936559
MDX-1105 is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target B7-H1/PD-L1/CD274, a protein implicated in the negative regulation of immune responses. This antibody features a human IgG4SP subtype heavy chain and has a predicted molecular weight of approximately 150 kDa. For experimental control purposes, Human IgG4 kappa, Isotype Control serves as the appropriate isotype control for MDX-1105, ensuring accurate interpretation of results in research applications focused on immunomodulation and cancer immunotherapy.
Acrixolimab is a humanized IgG4-κ monoclonal antibody designed to selectively target PD-1 (Programmed Death-1). This antibody is engineered to bind with high specificity to the PD-1 receptor, thereby modulating immune responses and enhancing immune cell activity. Acrixolimab is primarily used in research focused on immunotherapy and the study of immune checkpoint pathways in oncology.
Synonyms: RO-7121661
Lomvastomig is a human IgG1 κ monoclonal antibody targeting PDCD1 and HAVCR2. For optimal experimental control, it is recommended to use Human IgG1 kappa as an isotype control.
Synonyms: RO-7247669
Tobemstomig is a humanized IgG1 κ monoclonal antibody that targets both PDCD1 and LAG3. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control. This dual specificity enhances its potential for research into immune checkpoint pathways and their role in immunotherapy.
Itanistomig is a bispecific antibody designed to target CD274 and CD47. Structurally characterized as VH-G1CH1-h-H-γ1_L-κ-L-κ, this antibody facilitates dual engagement with these critical immune checkpoint proteins, enhancing the potential for immune system modulation in therapeutic applications. Itanistomig is engineered for high specificity and affinity, making it a valuable tool in research focused on cancer immunotherapy and immune regulation.
Synonyms: MK-3475 (anti-PD-1; Lambrolizumab (anti-PD-1
Pembrolizumab is a humanized IgG4 monoclonal antibody that functions as a programmed death-1 (PD-1) inhibitor. It effectively blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This inhibition prevents the suppression of T-cell activity, typically mediated by PD-1 signaling in cells expressing these ligands, thereby enhancing the immune response against tumor cells. Pembrolizumab is utilized extensively in immunotherapy protocols for various cancers, leveraging its ability to modulate immune system responses.
Abazistobart is a chimeric and humanized monoclonal antibody designed to act as both an immunostimulant and an antineoplastic agent. It specifically targets the programmed cell death protein 1 (PDCD1), effectively blocking its signaling pathway. This blockade results in the activation of the immune system and exhibits antineoplastic activity, making Abazistobart a valuable tool in cancer research.
Synonyms: HLX20
Opucolimab is a recombinant human monoclonal antibody targeting PD-L1 (Programmed Death-Ligand 1). This antibody is specifically designed for the development of antibody-drug conjugates. Opucolimab is primarily utilized in research focused on the treatment of advanced solid tumors, providing a critical tool for investigations into cancer immunotherapy.
Synonyms: CS1003
Nofazinlimab (CS1003) is a humanized IgG4 monoclonal antibody targeting PD-1. This antibody is specifically designed for use in research involving unresectable hepatocellular carcinoma (uHCC), offering a promising tool for investigating the modulation of immune checkpoint pathways in cancer immunotherapy.
